Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer
Dr Meredith Pelster speaks to ecancer about the first results from the global registrational AZUR-1 trial, which evaluated dostarlimab monotherapy in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced rectal cancer.
This patient population can be particularly responsive to PD-1 blockade, potentially avoiding the need for standard treatment with chemotherapy, radiotherapy and surgery.
Among 144 patients with at least 12 months of follow-up, 68% achieved a sustained clinical complete response for at least 12 months after treatment, as assessed by investigators.
The combined rate of sustained clinical complete response or pathological complete response was 76%.
No recurrences have been reported to date among patients achieving a clinical or pathological complete response, and 71% of all enrolled patients remained under surveillance with no evidence of disease progression after dostarlimab alone.
Dr Pelster says the treatment was generally well tolerated, with grade 3 or higher immune-mediated adverse events reported in four patients.
These findings highlight the potential of dostarlimab to offer a chemotherapy, radiotherapy and surgery-free treatment approach for selected patients with dMMR/MSI-H rectal cancer.
Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer
Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps
Tarlatamab improves brain metastases control and survival compared to chemo in SCLC
Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer
Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer
Physical activity reduces fatigue and improves quality of life in colorectal cancer survivors
Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer
Consolidation treatment delays do not compromise survival in MRD-negative adult ALL
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer